Published in Cancer Weekly, May 26th, 2009
Rexahn’s Senior Business Development Director, Wendy Tsai, and Chief Business Officer, Rick Soni, will provide a strategic business update of Rexahn’s recent clinical and financing milestones, opportunities for licensing and alliances, and an overview of its R&D pipeline.
Rexahn currently has three drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.